Tenax Therapeutics Inc (TENX)

[skyticket1]

this was not a PR of the company but an official study: but wait there is no market because centuries ago some big company thought it was not worth pursuing, so it never will ?! and a different indication ?- and the world, opportunities, technology and demands have and will never change, haha...
This company has changed! agree, in the past they pretty much did everything wrong what could have done wrong but now.....

“This manuscript is the most updated and methodologically strongest meta-analysis on the effect of inodilators on mortality in cardiac surgery. Using Bayesian network meta-analyses techniques, we attempted ranking among different inodilators that have never properly been compared one each other, and identified levosimendan to be the best inodilator to improve survival in adult cardiac surgery.”

“These publications indicate that levosimendan is the best inodilator to improve survival in adult cardiac surgery patients and acts as a ‘safety net’ in this critical care setting,” said John Kelley, CEO of Tenax Therapeutics. “We believe the conclusions drawn in these publications are highly supportive of our LEVO-CTS trial design and expectations regarding our study results.”

The highlighted publications include:

“Preoperative and perioperative use of levosimendan in cardiac surgery: European expert opinion,” International Journal of Cardiology; Toller, et al. The publication provides a review of the scientific literature as well as consensus recommendations from a panel of 27 experts from 18 countries regarding the preoperative use of levosimendan in cardiac surgery patients. Their recommendations support the LEVO-CTS study design in several ways – specifically, the consensus publication recommends pre-operative dosing and use in low ejection fraction coronary artery bypass and valve surgery patients. Their conclusion also generally supports the LEVO-CTS study endpoints, stating:

“Clinical studies show that levosimendan effectively improves general and pulmonary haemodynamics in patients undergoing cardiac surgery, thereby reducing the need for inotropic agents and mechanical circulatory support, and additionally optimising renal and hepatic function. In general, the length of stay in the ICU and in the hospital is shortened. Overall, levosimendan treatment is considered as a kind of ‘safety net’ in the surgical setting.”
The article was first published online on February 24, 2015, and can be accessed here: http://www.internationaljournalofcardiology.com/article/S0167-5273(15)00149-7/abstract

“A Bayesian network meta-analysis on the effect of inodilatory agents on mortality,” British Journal of Anaesthesia; Greco, et al. Dr. Greco and his co-authors published the findings of a meta-analysis they conducted to assess differences in mortality associated with various inodilator products that are commonly used in critical care patients. Their study included 46 trials published between 1995-2014 and concluded that levosimendan appears to be the most efficacious inodilator product to improve survival when used in cardiac surgery patients. As stated in their conclusion:

“This manuscript is the most updated and methodologically strongest meta-analysis on the effect of inodilators on mortality in cardiac surgery. Using Bayesian network meta-analyses techniques, we attempted ranking among different inodilators that have never properly been compared one each other, and identified levosimendan to be the best inodilator to improve survival in adult cardiac surgery.”
The article was first published online on February 4, 2015, and the abstract can be accessed here: http://bja.oxfordjournals.org/content/early/2015/02/04/bja.aeu446.abstract